Boston Scientific Corp (BSX)vsLucid Diagnostics Inc (LUCD)
BSX
Boston Scientific Corp
$48.55
-0.55%
HEALTHCARE · Cap: $70.87B
LUCD
Lucid Diagnostics Inc
$1.01
-2.43%
HEALTHCARE · Cap: $187.53M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 401419% more annual revenue ($20.61B vs $5.13M). BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
LUCD
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Intrinsic value data unavailable for LUCD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Revenue surging 51.7% year-over-year
Areas to Watch
No major concerns identified
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -711.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : LUCD
The strongest argument for LUCD centers on Revenue Growth. Revenue growth of 51.7% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : LUCD
The primary concerns for LUCD are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 6.70 is elevated, increasing financial risk.
Key Dynamics to Monitor
BSX profiles as a mature stock while LUCD is a hypergrowth play — different risk/reward profiles.
LUCD carries more volatility with a beta of 1.08 — expect wider price swings.
LUCD is growing revenue faster at 51.7% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 29/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Lucid Diagnostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Lucid Diagnostics Inc. is a commercial stage medical diagnostic technology company. The company is headquartered in New York, New York.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?